CJC-1295 vs Sermorelin: GHRH Analogs Compared for Growth Hormone Research

Introduction

Growth hormone-releasing hormone (GHRH) analogs are essential tools for researchers studying the somatotropic axis. CJC-1295 No DAC (Modified GRF 1-29) and Sermorelin (GRF 1-29) are two of the most widely used GHRH analogs in research, sharing the same core 29-amino acid sequence derived from native GHRH but differing in key structural modifications that affect stability, half-life, and GH release profiles.

This article compares these two GHRH analogs for researchers designing growth hormone studies. CJC-1295 No DAC is available from Proxiva Labs with verified purity documentation.

CJC-1295 No DAC (Modified GRF 1-29) Overview

Mechanism of Action

CJC-1295 No DAC is a modified version of the first 29 amino acids of human GHRH, with four amino acid substitutions at positions 2, 8, 15, and 27. These substitutions were specifically engineered to prevent degradation by dipeptidyl peptidase-IV (DPP-IV), the enzyme responsible for rapid inactivation of native GHRH and unmodified GRF 1-29. The result is a peptide with significantly improved metabolic stability and a half-life of approximately 30 minutes, compared to less than 10 minutes for native GHRH.

The “No DAC” designation indicates the absence of the Drug Affinity Complex (a maleimidopropionic acid-lysine linker), which in the DAC version extends the half-life to several days through albumin binding. The No DAC formulation produces more physiological pulsatile GH release, preferred by most researchers studying natural GH secretory dynamics.

Key Characteristics

• Half-life: ~30 minutes (vs ~8 minutes for native GHRH)
• DPP-IV resistance: Excellent (4 protective substitutions)
• GH release: Amplified pulsatile pattern, physiological rhythm maintained
• IGF-1 effect: Sustained elevation with repeated dosing protocols

Sermorelin (GRF 1-29) Overview

Mechanism of Action

Sermorelin is the unmodified first 29 amino acids of human GHRH, representing the minimally active fragment of the full 44-amino acid hormone. It retains full GHRH receptor binding affinity, as the first 29 residues contain the complete receptor-binding domain. However, without the protective amino acid substitutions found in CJC-1295, sermorelin is rapidly degraded by DPP-IV in circulation, resulting in a very short half-life of approximately 10-12 minutes.

Sermorelin has the distinction of being the first GHRH analog to receive FDA approval, granted in 1997 under the brand name Geref for diagnostic evaluation of pituitary GH secretory capacity. Its clinical history provides a substantial safety and pharmacological database (Walker, 2006, Ann Pharmacother, 40(5):895-899, PMID: 16670364).

Key Characteristics

• Half-life: ~10-12 minutes
• DPP-IV resistance: None (native sequence)
• GH release: Brief pulse, rapidly terminated
• FDA history: Approved 1997 (Geref), discontinued 2008

Key Differences

Research Applications

GH Pulse Amplitude Studies

CJC-1295 No DAC’s extended half-life produces more robust GH pulse amplitudes compared to sermorelin, as the prolonged receptor occupancy allows greater cumulative GH release per dose. For researchers measuring GH pulse amplitude as a primary endpoint, CJC-1295 provides a stronger signal with more consistent inter-dose reproducibility.

Physiological GH Pattern Research

Both compounds maintain the physiological pulsatile nature of GH release, unlike exogenous GH injection or the DAC version of CJC-1295. For studies investigating the biological significance of GH pulsatility versus tonic elevation, either compound preserves the natural secretory pattern while amplifying pulse amplitude.

Synergistic Stacking Research

Both GHRH analogs pair effectively with GHRPs (growth hormone-releasing peptides) such as ipamorelin, which stimulates GH through the ghrelin receptor. The GHRH + GHRP combination produces synergistic GH release exceeding either agent alone. CJC-1295 No DAC’s longer half-life may provide a wider effective window for this synergistic interaction compared to sermorelin’s brief activity period.

Researchers may also consider tesamorelin, a stabilized GHRH analog with a different clinical research profile, particularly for body composition studies.

Practical Research Considerations

Sermorelin’s very short half-life means that timing of blood draws or endpoint measurements relative to administration is critical. A delay of even 15 minutes may miss the peak GH response. CJC-1295 provides a broader sampling window, reducing the impact of timing variability on study results. For multi-site studies where precise timing control is challenging, CJC-1295 offers more forgiving pharmacokinetics.

Browse our complete selection of research peptides and explore our research guides for protocol guidance.

Conclusion

CJC-1295 No DAC and sermorelin are both GHRH receptor agonists that stimulate pulsatile GH release, but CJC-1295’s engineered DPP-IV resistance provides a substantially longer half-life, higher GH pulse amplitudes, and greater dosing flexibility. Sermorelin offers the advantage of a previously FDA-approved safety database and a completely native GHRH receptor interaction, but its rapid degradation limits its practical utility in many research designs. For most modern GH-axis research protocols, CJC-1295 No DAC has become the preferred GHRH analog due to its superior pharmacokinetic profile.

Shop CJC-1295 No DAC and other GH peptides at Proxiva Labs. All products verified by independent purity testing.

This article is for informational purposes only. All compounds mentioned are strictly for research use. Consult applicable regulations before purchasing research compounds.